Trametinib dimethyl sulfoxideProduct ingredient for Trametinib

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.^4,3 It was first approved by the FDA in May 2013 for the treatment of melanoma.⁴ It was later approved by Health Canada on July 18, 2013 ⁹ and by the European Commission on June 30, 2014.⁸ Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with dabrafenib, a BRAF inhibitor, for improved therapeutic efficacy. Originally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.⁴